\
[TechWorldNews | Reporter Jiseong Park]
REV-MED (CEO Edward BG Shin) announced the successful presentation of its autologous stem cell-related products at MEDICA 2024, held in Düsseldorf, Germany.
The event is a globally renowned medical device exhibition, with participation from 72 countries and over 6,000 companies, attracting approximately 80,000 visitors. REV-MED, recognized for its strong export performance, has expanded its business from minimally manipulated biological medical devices to laser medical devices, establishing itself as a key player both domestically and internationally.
Among the showcased products, the NovaStem kit stood out as a Class III medical device developed with proprietary technology. It enables the extraction of concentrated stem cells and various growth factors from autologous blood and bone marrow. The extracted cells are utilized in various fields, including tissue regeneration, and recent foundational research has shown potential applications in the field of autoimmune diseases.
A company representative stated, "Through MEDICA 2024, we were able to showcase our technological capabilities to the world and aim to solidify our position as a global leader in the bioindustry leveraging biological substances."
In 2024, REV-MED actively participated in more than 25 domestic and international conferences and exhibitions, highlighting the excellence of its technology.
Source: TechWorldNews https://www.epnc.co.kr/
[TechWorldNews | Reporter Jiseong Park]
REV-MED (CEO Edward BG Shin) announced the successful presentation of its autologous stem cell-related products at MEDICA 2024, held in Düsseldorf, Germany.
The event is a globally renowned medical device exhibition, with participation from 72 countries and over 6,000 companies, attracting approximately 80,000 visitors. REV-MED, recognized for its strong export performance, has expanded its business from minimally manipulated biological medical devices to laser medical devices, establishing itself as a key player both domestically and internationally.
Among the showcased products, the NovaStem kit stood out as a Class III medical device developed with proprietary technology. It enables the extraction of concentrated stem cells and various growth factors from autologous blood and bone marrow. The extracted cells are utilized in various fields, including tissue regeneration, and recent foundational research has shown potential applications in the field of autoimmune diseases.
A company representative stated, "Through MEDICA 2024, we were able to showcase our technological capabilities to the world and aim to solidify our position as a global leader in the bioindustry leveraging biological substances."
In 2024, REV-MED actively participated in more than 25 domestic and international conferences and exhibitions, highlighting the excellence of its technology.
Source: TechWorldNews https://www.epnc.co.kr/